To be more specific in this era of treatment individualization, it may not be too distant future to enable and aid the clinicians to stratify and integrate the overall risk factors with respect to disease molecular profile to the traditional host and tumour staging (the significant ones viz., TP53, cyclin D1 antisense, EGFR overexpression, HPV genome in tumour tissue) and optimize treatment strategies in the treatment naive individuals. This evidence concerns the gene EGFR and neoplasm.